The Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines from 2019 for the treatment of colorectal cancer only recommend that patients with unresectable colorectal cancer be treated with pembrolizumab and no recommendations were made for anti-PD-1/PDL1 inhibitors as a neoadjuvant therapy [23]. The gene discussed is PDCD1; the disease is colorectal cancer.